Liver disease is one of the leading causes of lost years of working life in Europe, second only to ischaemic heart disease. And, without a doubt, non-alcoholic fatty liver disease (NAFLD) is the most frequent cause of chronic liver disease in our environment. Progress in the prevention and treatment of NAFLD is closely linked to the understanding of this disease from the pathophysiological and clinical point of view as a basis for a better definition of risk factors, the establishment of adequate predictors of disease progression, the definition of new biomarkers and the individualisation of therapy adjusted to the characteristics of each patient.
Date: 9 to 11 May and 16 to 18 May 2022
Directors:
Dr. Javier Crespo
Gastroenterology and Hepatology Unit, Marqués de Valdecilla University Hospital, IDIVAL, Santander, Spain.
Dr. Jeffrey Lazarus
Barcelona Institute for Global Health (ISGlobal), Hospital Clínic, University of Barcelona, Barcelona, Spain.
Dra. Paula Iruzubieta
Gastroenterology and Hepatology Unit, Marqués de Valdecilla University Hospital, IDIVAL, Santander, Spain.
You can access the program in this link. There you can find the instructions to join. Registration is need.
